Post by
Noteable on Jan 29, 2024 1:17pm
Keytruda resistance shown as a monotherapy in anal cancer
January 25, 2024 - In the phase II study, the ORR to pembrolizumab monotherapy was 9.4% and the median progression-free survival was 2.2 months.
Conclusions Pembrolizumab has durable efficacy in a rare subset of anal cancers. However, despite persistence of HPV infection, indicated by circulating HPV DNA, most advanced anal cancers have low numbers of tumor-associated CD8+PD-1+ T cells and are resistant to pembrolizumab.
https://jitc.bmj.com/content/12/1/e008436?rss=1
This study demonstrates that immune checkpoint inhibitors are relatively ineffective as a monotherapy and require combination with ONCY's oncolytic virus pelareorep to affect a favorable tumor microenvironment (TME) for the addition of checkpoint inhibitors and the enhancement of CD8 + PD-(L)1 + T cells for an effective anti-tumor response.
https://jitc.bmj.com/content/12/1/e008436?rss=1
Comment by
Noteable on Jan 30, 2024 12:02pm
This is all good news ... pelareorep, when added to an immune checkpoint inhibitor, results in a 4 fold improvement in ORR, which demonstratres synergy with an immune checkpoint inhibitor and is considered a biomarker for future response rate.
Comment by
Noteable on Jan 30, 2024 5:11pm
The facts show that ... pelareorep, when added to an immune checkpoint inhibitor, results in a 4 fold improvement in ORR, which demonstratres synergy with an immune checkpoint inhibitor and is considered a biomarker for future response rate. Couldn't be much more factual or clearer than this.
Comment by
13X2413 on Jan 30, 2024 5:14pm
Quentin's comments are much clearer and specific to ONC.
Comment by
Azzak34 on Jan 30, 2024 5:20pm
So, from his post that you have cited. Reiterate the facts!!!
Comment by
Noteable on Mar 25, 2024 10:24pm
Merck (MSD) is now looking to combine other I/O agents with Keytruda to enhance the immune checkpoint inhibitors effectiveness. ONCY's pelareorep is demonstrating that it fits Merck's need.
Comment by
13X2413 on Feb 05, 2024 8:59pm
Nice. But why is share price at $1.50?